NeuroOne Medical Technologies (NMTC)

NeuroOne’s platform is based on flexible, low-profile electrodes that can be used for applications including cortical recording, stereo electroencephalography, continuous EEG monitoring, deep brain stimulation research, and radiofrequency ablation. Its commercial products include the Evo Cortical Electrode line, the Evo sEEG Electrode line, and the OneRF Ablation System. These devices are designed to help physicians identify abnormal electrical activity, localise seizure sources, and, in certain settings, deliver therapy through targeted energy or stimulation.

The company operates as a specialised device developer rather than a diversified healthcare manufacturer. Its revenue opportunity depends on product clearances, hospital adoption, physician familiarity, reimbursement dynamics, manufacturing execution, and partnerships that can expand distribution. Because many neurological procedures require high precision and strong safety performance, clinical usability and regulatory compliance are central to the company’s prospects.

For investors, NMTC represents exposure to the intersection of neurodiagnostics, neuromodulation, and minimally invasive brain therapy. Its differentiation lies in applying thin-film electrode designs to multiple clinical workflows, potentially allowing a single technology base to support recording, monitoring, ablation, and stimulation applications in complex neurological care.